We have witnessed major improvements in our ability to detect and stage prostate cancer and have benefited from a sustained decrease in the death rate from this common disease due, in part, to the introduction of serum Prostate Specific Antigen (PSA) into clinical practice in the late 1970's. Now in 2004, in the wake of the """"""""PSA era"""""""" discoveries, we continue to perform diagnostic biopsies unnecessarily on 75% of men with abnormal PSA levels, finding 1:4 with disease, we continue to understage nearly 30% of men with presumed localized disease, and we continue to lack additional clinically validated prostate cancer biomarkers. Also, as the """"""""baby boomer"""""""" men reach their 60's, it is anticipated that the number of men over age 50 will increase greatly, reaching 80 million by year 2015. This, coupled with the fact that there are nearly 20 million men in the U.S. alone who have had one negative prostate biopsy yet still are risk for prostate cancer and can no longer rely on PSA as their biomarker of choice. Clearly further discovery, characterization and validation of potential biomarkers for the early detection of prostate cancer are greatly needed - The mission of the Early Detection Research Network. In this competitive renewal proposal we will outline our progress between 1999 and 2004 as an EDRN Clinical and Epidemiological Center. We will demonstrate our ability to accrue patients, archive an impressive and clinically valuable biorepository of specimens, take part in collaborative research within the EDRN network, Industry and non-EDRN investigators, actively take part in the governance of the EDRN and publish key biomarker findings. Within this renewal we will also outline our proposed continuation/enhancements of our biorepository, anticipated development and participation in validation studies, characterization of novel tumor markers (pre-validation), preliminary pilot studies of biomarkers, evaluation of biomarker technologies and development of multivariate tumor marker models for complex evaluation of multiple tumor markers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA086323-10
Application #
7617185
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Kagan, Jacob
Project Start
2000-04-13
Project End
2011-06-30
Budget Start
2009-04-10
Budget End
2011-06-30
Support Year
10
Fiscal Year
2009
Total Cost
$718,527
Indirect Cost
Name
Johns Hopkins University
Department
Urology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Carleton, Neil M; Zhu, Guangjing; Gorbounov, Mikhail et al. (2018) PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis. Prostate 78:547-559
Carleton, Neil M; Lee, George; Madabhushi, Anant et al. (2018) Advances in the computational and molecular understanding of the prostate cancer cell nucleus. J Cell Biochem 119:7127-7142
Loeb, Stacy; Shin, Sanghyuk S; Broyles, Dennis L et al. (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120:61-68
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ankerst, Donna P; Koniarski, Tim; Liang, Yuanyuan et al. (2012) Updating risk prediction tools: a case study in prostate cancer. Biom J 54:127-42
Trock, Bruce J; Brotzman, Michelle J; Mangold, Leslie A et al. (2012) Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 110:56-62
(2012) Retraction: Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate 72:1157
Ewing, Charles M; Ray, Anna M; Lange, Ethan M et al. (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141-9
Makarov, Danil V; Loeb, Stacy; Magheli, Ahmed et al. (2011) Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. World J Urol 29:11-4
Ivansson, E L; Juko-Pecirep, I; Erlich, H A et al. (2011) Pathway-based analysis of genetic susceptibility to cervical cancer in situ: HLA-DPB1 affects risk in Swedish women. Genes Immun 12:605-14

Showing the most recent 10 out of 60 publications